← Issue №20/ week of Nov 15, 2026/ the whole section, in full

Colorectal, in full.

All 5 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 5, in full

most clinically useful first · the 2 the issue led with are ruled in green
Colorectal retrospective · n=1,733 · Nov 13, 2026 · Clin Transl Gastro · IF 3.4

Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry.

New evidencecolorectal cancer screeningbiomarkerepidemiology
What it foundPatients with a prior normal colonoscopy had 19.1% prevalence of advanced colorectal neoplasia after a positive mt-sDNA test, half the odds of advanced findings compared to those without prior colonoscopy (OR 0.51; 95% CI 0.41-0.62).
ContextThis literature reports that the yield of advanced neoplasia following a positive multi-target stool DNA test in patients with a prior normal colonoscopy remains an area of investigation.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

… Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. … ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Anderson JC … Butterly LF · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
Colorectal prospective cohort · n=17,068 · Nov 11, 2026 · Am J Clin Nutrition · IF 6.5

Folate and folic acid intake in relation to molecular subtypes of colorectal cancer: pooled analyses of up to 8970 cases and 8098 control participants.

New evidenceepidemiologybiomarkermicrosatellite instabilitycolorectal cancer
Clinical takeawayNo clinical action yet: pooled observational data from case-control and cohort studies, with intake from food frequency questionnaires or diet histories; the study does not test giving folate or folic acid.
What it foundTotal folate intake and folate supplement use were inversely associated with colorectal cancer risk, with a stronger inverse association for CIMP-low/negative vs. CIMP-high tumors (pdifference=0.07). Dietary folate showed a weaker association, and there was a null association for the Jass Type 2 subtype.
ContextHigher folate intake has been associated with modest reductions in colorectal cancer risk; across 8970 cases and 8098 controls, the authors judge the putative protective effect broad, not limited to BRAF, KRAS, MSI or CIMP subtypes.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Van Guelpen B … Peters U · American Journal of Clinical Nutrition · IF 6.5 · PubMed ↗Permalink
Colorectal review · Nov 12, 2026 · Lancet · IF 98.4

Lynch syndrome.

Guideline / reviewLynch syndromebasic sciencetranslationalguideline
Clinical takeawayColonoscopic surveillance, aspirin chemoprevention and risk-reducing surgery are effective but need gene-specific, individualised application; carriers are found through universal tumour MMR testing followed by germline testing and cascade screening of relatives.
What it foundLynch syndrome affects approximately one in 350-450 individuals, and most carriers are undiagnosed. Universal tumour testing for MMR deficiency has transformed case identification and enabled targeted germline testing and cascade screening of relatives, but implementation is inconsistent, with attrition across diagnostic pathways and inequities in access.
ContextA review spanning biology, diagnosis, prevention and treatment, including substantial checkpoint-inhibitor benefit in MMR-deficient tumours and emerging vaccine strategies; it stresses equitable, effective health-system delivery.
Measured against the standard of care· ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.)

… Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. … Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Polyposis syndromes are now governed by ACG 2026 (Mankaney G, Idos GE, Stoffel EM, Weiss JM, Shah S, Qayed E, Harnegie MP, Burke CA; Am J Gastroenterol 2026;121(9):2086-2120, GRADE). For polyposis, it replaces the 2015 ACG hereditary GI cancer guideline (Syngal et al.), Recommendations 10-11. Germline multigene panel testing is recommended for anyone with 20 or more cumulative lifetime colorectal adenomas (strong recommendation) and suggested for 10-19 adenomas (conditional, because the yield is lower). The 2015 polyposis testing trigger was more than 10 adenomas. Asymptomatic APC carriers, biallelic MUTYH carriers, and untested people at risk for AFAP or MAP should have a baseline colonoscopy by age 18-20. Colonoscopy then repeats every 1-3 years depending on the histology, size and number of polyps. It moves to every 3-6 months when there are many or large polyps, or high-grade dysplasia. This replaces the 2015 schedules of annual sigmoidoscopy/colonoscopy from puberty for classic FAP, colonoscopy every 1-2 years from the late teens for AFAP, and from age 25-30 for MAP. Whether at-risk children in classic-FAP families still start younger is not stated in the excerpt available at review; confirm against the full text. For FAP, AFAP and MAP, upper endoscopic surveillance that includes viewing the duodenal papilla is suggested over no surveillance (Recommendation 8, conditional). Duodenal management is still staged by Spigelman, which has acknowledged limits in sensitivity for duodenal and papillary cancer. The 2026 starting age and intervals for upper endoscopy are not stated in the excerpt available at review. The choice of operation (total colectomy with IRA, IPAA, or end ileostomy) is individualized by genotype, polyp distribution, cancer status, comorbidity and preference, with early referral to an experienced colorectal surgeon. IRA is generally favored with up to about 20 rectal adenomas and IPAA above that, though this is not a fixed cutoff. The rectum or pouch should be checked endoscopically every year after IRA or IPAA. Chemoprevention is recommended against as a substitute for colectomy when surgery is indicated. Whether 2026 keeps annual thyroid ultrasound is not stated in the excerpt available at review. Lynch syndrome and serrated polyposis syndrome are outside the 2026 document, so the Lynch and SPS parts of the standard on file were not re-verified here: Lynch colonoscopy every 1-2 years from age 20-25, gyn and upper-GI surveillance, and SPS colonoscopy every 1-3 years with removal of polyps over 5 mm.

ACG 2026 (adenomatous polyposis: Mankaney et al., Am J Gastroenterol 2026;121:2086-2120) / ACG 2015 (Lynch, SPS: Syngal et al.) · reviewed 2026-10-11 ↗
Ryan NAJ … Smith T · The Lancet · IF 98.4 · PubMed ↗Permalink
Colorectal meta analysis · Nov 9, 2026 · J Clin Gastro · IF 2.9

Cost-effectiveness Analysis of SUTAB or SUFLAVE Versus Polyethylene Glycol-Electrolyte Solution or Over-the-Counter Bowel Preparations for Screening Colonoscopy.

New evidencecost-effectivenesscolorectal cancer screeninghealth services
Clinical takeawayFor average-risk US adults 45 and older, this model favours SUTAB or SUFLAVE on cost alone; QALY differences were under 0.001, and colonoscopy adherence and preparation adequacy were the most influential inputs.
What it foundSUTAB and SUFLAVE saved $439 and $361 per person vs PEG-ELS, and $822 and $744 vs OTC, with nearly equivalent QALYs (differences <0.001) compared to PEG-ELS and OTC.
ContextA modelled result: an 8-state Markov model calibrated to US Preventive Services Task Force microsimulation models, in which better preparation reduces repeat colonoscopies with minimal effect on QALYs and CRC detection.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakethe choice of bowel preparation for screening colonoscopy

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Zur RM … Halberg DL · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Colorectal retrospective · n=168 · Nov 12, 2026 · Dis Colon Rectum · IF 3.5

Comparative Outcomes of CREATE Versus Conventional Double-Stapling Technique for Ultralow Rectal Cancer: A Multicenter Propensity-Matched Analysis.

New evidencerectal cancercolorectal surgery
Clinical takeawayAn early functional advantage from a retrospective matched cohort with selective eligibility for CREATE and LARS assessed after stoma reversal; it was gone by 24 months, and anastomotic leakage and 3-year survival did not differ significantly.
What it foundIn a retrospective propensity-matched comparison (60 CREATE vs 108 double-stapling patients), major LARS was 42.9% vs 72.5% at 6 months (p=0.01) and 35.3% vs 66.7% at 12 months (p=0.007), with no difference at 24 months (p=1.00). Anastomoses were higher (3.0 vs 2.0 cm) and distal margins shorter (1.0 vs 1.2 cm); 3-year disease-free (88.4% vs 86.1%) and overall survival (89.3% vs 91.5%) did not differ significantly.
ContextCREATE (conformal resection after eversion with asymmetric twice stapling) was developed to refine distal transection and stapled coloanal anastomosis in ultralow rectal cancer; three Chinese tertiary centres, 2012 to 2021.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Hu G … Tang J · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Back to issue №20 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS